Drugs / Thero2-01S22
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05698186 | May 2023 → May 2027 expected | HER2 positive breast carcinoma | Institut de cancérologie Strasbourg Europe | Not yet recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Thero2-01S22 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05698186 ↗ |